Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Feb 2023
UK: More health is associated with more cardiovascular disease (CVD) and higher triglycerides...
Read Full NewsTrial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.
The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.
COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD
FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD
FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension
Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial
FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates
1.
Non-Hodgkin lymphomas that are indolent have been linked to psychological distress.
2.
Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.
3.
'Dawson's Creek' Star Has Cancer; Radiotherapy Tattoos; Case of 'Petticoat' Cancer
4.
Acupuncture may alleviate nocturia in men treated for prostate cancer
5.
More evidence links physical activity with improved cancer survival
1.
Clinical Analysis of Prostate Cancer
2.
What Is A Normal Fibrinogen Level, And How Can It Affect Your Health
3.
New Anticoagulants: Balancing Efficacy and Safety in Patients with Atrial Fibrillation
4.
Case Study: Genomic Medicine in Precision Oncology
5.
Asymptomatic Thrombocytopenia: Unraveling the Enigma of Low Platelet Counts Without Symptoms
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Navigating the Complexities of Ph Negative ALL - Part III
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge